Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2

作者：

Lin, Ningjing ^{[1
]}

Sun, Xiuhua ^{[2
]}

Zhou, Hui ^{[3
]}

Zou, Liqun ^{[4
]}

Zhou, Keshu ^{[5
]}

Liu, Lihong ^{[6
]}

Yang, Haiyan ^{[7
]}

Hu, Kai ^{[8
]}

Cai, Qingqing ^{[9
]}

Liu, Yao ^{[10
]}

Jin, Jie ^{[11
]}

Zhang, Liling ^{[12
]}

Li, Wenyu ^{[13
]}

Guo, Ye ^{[14
]}

Yang, Wei ^{[15
]}

Luo, Feng ^{[16
]}

Li, Yanyan ^{[16
]}

Zhang, Mengqi ^{[16
]}

Lu, Feinan ^{[16
]}

Song, Yuqin ^{[17
]}

Zhu, Jun ^{[18
]}

机构：

[1] Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[4] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[5] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China

[6] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[7] Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China

[8] Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China

[9] Sun Yat Sen Univ, Canc Cente, Guangzhou, Peoples R China

[10] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China

[11] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[12] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China

[13] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[14] Shanghai East Hosp, Shanghai, Peoples R China

[15] China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China

[16] Overland Pharmaceut, Shanghai, Peoples R China

[17] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[18] Peking Univ, Canc Hosp, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173645

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
Peters, Anthea
Nowakowski, Grzegorz S.
Dabas, Rosy
Amoloja, Theresa
Xue, Zhenyi
Koch, Caroline
Waltl, Eva E.
Fleury, Isabelle
BLOOD, 2022, 140 : 3811 - 3813
[32] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Maria Jose
Schuster, Stephen J.
Salles, Gilles
Maziarz, Richard T.
Anak, Ozlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
CANCER RESEARCH, 2018, 78 (13)
[33] Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hamadani, Mehdi
Graham, Christopher
Liao, Laura
Zhang, Kate
Strat, Hannah
Ungar, David
Ai, Weiyun
Chen, Lei
Carlo-Stella, Carmelo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S373 - S373
[34] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Hutchings, Martin
Sureda, Anna
Terol, Maria Jose
Albareda, Francesc Bosch
Corradini, Paolo
Larsen, Thomas Stauffer
Dominguez, Antonio Rueda
Panchal, Anesh
Bottos, Alessia
Carlile, David
Wang, Yanjie
De L'Etang, Audrey Filezac
Tandon, Maneesh
Sellam, Gila
Gritti, Giuseppe
BLOOD, 2021, 138
[35] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
Li, Yin
Li, Chunfan
Lv, Kebing
Wang, Shixuan
Li, Fei
AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
[36] New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment
Tauveron-Jalenques, Urbain
Bay, Jacques-Olivier
BULLETIN DU CANCER, 2023, 110 (05) : 476 - 477
[37] Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
Caimi, Paolo F.
Ai, Weiyun Z.
Alderuccio, Juan Pablo
Ardeshna, Kirit M.
Hamadani, Mehdi
Hess, Brian
Kahl, Brad S.
Radford, John
Solh, Melhem
Stathis, Anastasios
Zinzani, Pier Luigi
Wang, Ying
Qin, Yajuan
Wang, Luqiang
Xu, Zhiying Cindy
Stella, Carmelo Carlo-
HAEMATOLOGICA, 2024, 109 (04) : 1184 - 1193
[38] Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial
Bishop, Michael R.
Maziarz, Richard Thomas T.
Waller, Edmund K.
del Corral, Christopher
Tiwari, Ranjan
Anak, Ozlem
Awasthi, Rakesh
Romanov, Vadim V.
Schuster, Stephen J.
BLOOD, 2018, 132
[39] [18F]FDG PET/CT biomarkers in patients with Relapsed/ Refractory Diffuse Large B-cell Lymphoma treated with Loncastuximab tesirine
Zanca, R.
Improta, C. M.
Magagnoli, M.
Mazza, R.
Rodari, M.
Carlo-Stella, C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S579 - S579
[40] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
Duell, Johannes
Jurczak, Wojciech
Liberati, Anna Marina
Halka, Janusz
Carbo, Esther Pena
Costa, Pau Abrisqueta
Maddocks, Kami J.
Dreyling, Martin
Rosenwald, Andreas
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
BLOOD, 2022, 140 : 6596 - 6598

← 1 2 3 4 5 →